Full Press Release Details
NuCana Announces Presentations at the AACR-NCI-EORTC
Conference on Molecular Targets and Cancer Therapeutics 2023
Edinburgh, United Kingdom, September 18, 2023 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 being held October 11-15, 2023 in Boston,
The details of NuCana s presentations at the meeting are as follows:
Abstract title: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for
second-line treatment of patients with advanced colorectal cancer (NuTide:302)
Session: Poster Session B
Session date and time:
Friday, October 13 from 12:30pm-4:00pm
Presenting Author: Dr. Khurum Khan
Abstract title: Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI +
bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323)
Session: Poster Session B
Date and time: Friday, October 13 from 12:30pm-4:00pm
Presenting Author: Professor Richard Wilson
Abstract title: Phase Ib/II open label, multi-arm, parallel cohort dose finding and expansion study of NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors or docetaxel in patients with lung cancer (NuTide:303)
Session: Poster Session C
Session date and time: Saturday, October 14 from 12:30pm-4:00pm
Presenting Author: Professor Richard Wilson
title: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study
Session: Poster Session C
Session date and time: Saturday, October 14 from 12:30pm-4:00pm
Presenting Author: Professor Sarah Blagden
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide
technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and
hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of
nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is
currently being evaluated in three ongoing clinical studies: a Phase 1b/2 study (NuTide:302) in combination with leucovorin, irinotecan or oxaliplatin, and bevacizumab in patients with metastatic colorectal cancer; a randomized Phase 2 study
(NuTide:323) in combination with leucovorin, irinotecan, and bevacizumab for the second-line treatment of patients with advanced colorectal cancer; and a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in
combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. NUC-7738 is a
transformation of 3 -deoxyadenosine, a novel anti-cancer nucleoside analog. NUC-7738 is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are
based on the beliefs and assumptions and on information currently available to management of NuCana plc (the Company ). All statements other than statements of historical fact contained in this press release are forward-looking
statements, including statements concerning the Company s planned and ongoing clinical studies for the Company s product candidates and the potential advantages of those product candidates, including
NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company s
goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical
results; and the sufficiency of the Company s current cash, cash equivalents and marketable securities to fund its planned operations into 2025. In some cases, you can identify forward-looking statements by terminology such as may,
will, should, expects, plans, anticipates, believes, estimates, predicts, potential or continue or the negative of these terms or
other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company s actual results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the Risk Factors section of the
Company s Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission ( SEC ) on April 4, 2023, and subsequent reports that the
Company files with the SEC. Forward-looking statements represent the Company s beliefs and
assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future
results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the
forward-looking statements to actual results or to changes in its expectations.
For more information, please contact:
Chief Executive Officer